Similar articles

• Autoimmune disorders in diabetes.

  Boitard C, Debray-Sachs M, Bach JF. Boitard C, et al. Adv Nephrol Necker Hosp. 1986;15:281-305. Adv Nephrol Necker Hosp. 1986. PMID: 3082114 Review.
• Faulty major histocompatibility complex class I function linked to autoimmune diabetes.

  Faustman D. Faustman D. Transplant Proc. 1992 Dec;24(6):2874-6. Transplant Proc. 1992. PMID: 1465979 No abstract available.
• T-splenocytes from non-obese diabetic mice binding to xenogeneic pancreatic beta-cells in vitro. Implication of the alpha/beta T-cell receptor and of major histocompatibility complex class II molecules from target cells.

  Martignat L, Feve B, Ouary M, Pogu S, Charbonnel B, Saï P. Martignat L, et al. J Autoimmun. 1993 Dec;6(6):753-69. doi: 10.1006/jaut.1993.1062. J Autoimmun. 1993. PMID: 8155255
• Autoimmune endocrine diseases.

  De Baets MH. De Baets MH. Year Immunol. 1989;4:264-75. Year Immunol. 1989. PMID: 2564710 Review. No abstract available.
• In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.

  von Herrath MG, Coon B, Lewicki H, Mazarguil H, Gairin JE, Oldstone MB. von Herrath MG, et al. J Immunol. 1998 Nov 1;161(9):5087-96. J Immunol. 1998. PMID: 9794447